Suppression of Occurrence and Advancement of β-Catenin-accumulated Crypts, Possible Premalignant Lesions of Colon Cancer, by Selective Cyclooxygenase-2 Inhibitor, Celecoxib

Yasuhiro Yamada,1 Naoki Yoshimi, Yoshinobu Hirose, Akira Hara, Masahito Shimizu, Toshiya Kuno, Masaki Katayama, Zheng Qiao and Hideki Mori
Department of Pathology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500-8705

Suppression of occurrence and advancement of premalignant lesions is important for cancer prevention. Our previous studies clarified that β-catenin-accumulated crypts, independent of aberrant crypt foci (ACF), are probably direct precursors of colon cancers in rats. Here we investigated the effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on the development of β-catenin-accumulated crypts in comparison with those on ACF. Male F344 rats were divided into 4 groups. Groups 1–3 were administered azoxymethane (AOM) s.c. at a dose of 15 mg/kg body weight, once weekly for 3 weeks to induce β-catenin-accumulated crypts. Groups 2 and 3 also received experimental diet containing celecoxib (500 and 1500 ppm, respectively) for 8 weeks, starting a week before the first dosing of AOM. At termination, the frequency and crypt multiplicity (number of crypts/lesion) of β-catenin-accumulated crypts of groups 2 and 3 were significantly less than that of group 1. Furthermore, numbers of silver-stained nucleolar organizer regions (AgNORs)/nucleus in β-catenin-accumulated crypts were also decreased by exposure to celecoxib. In this study, celecoxib had greater effects on the frequency and growth of β-catenin-accumulated crypts than on those of ACF. These findings represent additional evidence that β-catenin-accumulated crypts are premalignant lesions of colon cancer. The results also suggest that β-catenin-accumulated crypts could be a novel target for evaluation of possible chemopreventive agents against colon carcinogenesis, and indicate that possible chemopreventive effects of celecoxib on the initial stage of colon carcinogenesis may be related to modulation of cell proliferation activity in such early lesions.

Key words: Chemoprevention — Celecoxib — Colon carcinogenesis — Premalignant lesion — Rat

Colorectal cancer is one of the leading causes of cancer deaths all over the world and is therefore a major public health problem. During the last decade, numerous studies including molecular analysis have focused on discovery of possible chemopreventive agents against colon carcinogenesis. Several epidemiological and clinical studies have suggested an inverse association between risk of colon cancer and intake of nonsteroidal anti-inflammatory drugs (NSAIDs).1, 2) Studies in laboratory animals have also provided convincing evidence that exposure to various NSAIDs inhibits chemically induced colon carcinogenesis.3, 4) Although the precise mechanism by which NSAIDs prevent colon carcinogenesis is not clear, it may involve the inhibition of arachidonic acid metabolism by two cyclooxygenase (COX) isozymes, COX-1 and COX-2. It is known that commonly used NSAIDs inhibit the activity of both isozymes of COX. However, recent studies have focused on specific COX-2 inhibitors as potent chemopreventive agents for colorectal cancers.5, 6) Among COX-2 inhibitors, celecoxib is now regarded as the most prominent agent for the suppression of the development of colon tumors.5, 7)

Colon carcinogenesis is a representative multistep tumorigenesis with accumulating genetic alterations.8) Alterations in the APC or β-catenin gene are regarded as early and critical events during colon carcinogenesis and are therefore considered to play a gatekeeper role in development of colon cancers in both humans and rodents.9–11) Such mutations are suggested to result in accumulation of β-catenin protein.12, 13) Recently, β-catenin has been proved to function as a transcriptional activator when complexed with members of the T cell factor (Tcf) family of DNA binding proteins.14, 15) Furthermore, target genes of the β-catenin signaling pathway were identified as growth-promoting genes, such as c-myc and cyclin D1,16, 17) suggesting that the pathway is oncogenic.

Previously, we found the presence of altered crypts with excessive β-catenin in rat colonic mucosa that was predisposed to colon cancer.18, 19) In addition to the accumulation of the oncogenic β-catenin protein, such crypts harbored frequent mutations in the β-catenin gene.18) Histological observations also showed that β-catenin-accumulated crypts exhibit dysplasia, a hallmark of malignant potential.

1 To whom requests for reprints should be addressed.
E-mail: y-yamada@cc.gifu-u.ac.jp
and their size increased with time after carcinogen exposure. These findings clearly indicate that such early appearing lesions are premalignant lesions of colon cancer in rats. Interestingly, the β-catenin-accumulated crypts are generally independent of aberrant crypt foci (ACF) that were described as early appearing lesions and putative pre-neoplastic lesions of colon cancer. Importantly, the proliferative activity of crypts with accumulation of β-catenin is significantly higher than that of ACF. Therefore, it is reasonable to conclude that β-catenin-accumulated crypts are more likely to progress to malignant transformation than ACF.

The major aim of this study is to investigate the modifying effects of a specific COX-2 inhibitor, celecoxib, on β-catenin-accumulated crypts. Although, there are a number of reports demonstrating that chemopreventive agents, including celecoxib, inhibit the formation of ACF, this study seems to be the first report to investigate the effect of chemopreventive agent on the possible direct precursor of colon cancer.

**MATERIALS AND METHODS**

**Animals, carcinogen, test chemicals and diets** Male F344 rats (Shizuoka Laboratory Animal Center, Shizuoka) aged 4 weeks were used. All animals were housed in wire cages (3 or 4 rats/cage) with free access to drinking water and basal diet, CE-2 (CLEA Japan Inc., Tokyo), under controlled conditions of humidity (50±10%), lighting (12-h light/dark cycle) and temperature (23±2°C). A total of 28 rats were quarantined for 7 days and randomized into experimental and control groups (Fig. 1). Azoxymethane (AOM) was purchased from Sigma Chemical Co., St. Louis, MO. Celecoxib (SC-58635; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-sulfonamide) was kindly supplied by Searle Research and Development (St. Louis, MO). Experimental diets were made by mixing test chemicals in powdered basal diet CE-2 at a concentration of 500 or 1500 ppm. The dose levels of test compounds were determined on the basis of previous reports.

**Experimental procedure** A total of 28 male F344 rats were divided into 4 groups as shown in Fig. 1. Groups 1 through 3 were initiated with AOM by 3 weekly subcutaneous injections (15 mg/kg body weight). Rats in groups 2 and 3 were respectively fed the diets containing 500 and 1500 ppm celecoxib, starting one week before the first dose of AOM. Group 4 served as a control. The experiment was terminated 8 weeks after the start and all animals were sacrificed to assess the occurrence and growth of β-catenin-accumulated crypts. Immediately after the sacrifice, colons were removed, cut open along the longitudinal axis, fixed flat in 2% paraformaldehyde in 0.1 M liter phosphate-buffered saline (pH 7.4) for 24 h at 4°C. Colonic mucosal sections were examined by utilizing an en face preparation and 3- to 5-μm thick serial sections. We examined colonic mucosa in three different segments, distal, medium-distal, and proximal-medium, and a total of 112 segments were used for the analysis. The segments were stained with methylene blue and the frequency of ACF was determined. ACFs were distinguished from the surrounding ‘normal-appearing’ crypts by their increased size. For each case, 20–40 serial sections of crypts were prepared to investigate whole crypts from the mucosal surface to the crypt bottom.

**COX-2 immunohistochemistry** To determine the localization of COX-2 protein, we performed immunohistochemical analysis. For immunohistochemical analysis, the labeled streptavidin biotin method was performed using an LSAB KIT (DAKO, Glostrup, Denmark) with microwave accentuation. The paraffin-embedded sections were heated for 30 min at 65°C, deparaffinized in xylene, and rehydrated through graded alcohols at room temperature. A 0.05 M Tris-HCl buffer (pH 7.6) was used to prepare solutions and for washes between various steps. Incubations were performed in a humidified chamber. Sections were treated for 40 min at room temperature with 2% bovine serum albumin and incubated overnight at 4°C with primary antibodies against rat COX-2 protein (diluted 1:100, Transduction Laboratories, Lexington, KY). For each case, negative controls were performed on serial sections. For the control section, incubation with the primary antibody was omitted. Horseradish peroxidase activity was visualized by treatment with H₂O₂ and diaminobenzidine for 5 min. At the last step, the sections were weakly counterstained with hematoxylin. Immunoreactivities were regarded as positive if apparent stainings were detected in cytoplasm of early appearing lesions.

**Determination of β-catenin-accumulated crypts** Using specific antibody against β-catenin protein (diluted...
1:1000, Transduction Laboratories), immunohistochemistry was performed according to the same procedure as COX-2 immunohistochemistry. Two pathologists evaluated these immunoreactivities independently. At least two sections per preparation were examined for β-catenin immunohistochemistry, and samples were regarded as positive when apparent immunoreactivities in cytoplasm or nucleus were recognized in more than one section. β-Catenin-accumulated crypts were examined for their frequency and crypt multiplicity (number of crypts/lesion) of the lesion.

**Silver-stained nucleolar organizer regions (AgNORs)**

Analysis of AgNORs staining, which is thought to be a biomarker of cell proliferation, was carried out according to the method described previously, with minor modifications. β-Catenin-accumulated crypts in each group were used and two sections from the upper and lower portion of the mucosa were evaluated. AgNORs counts/nucleus were scored on AgNOR-stained sections by microscopy at a magnification of ×400.

**RESULTS**

**COX-2 overexpression**

Six of 10 β-catenin-accumulated crypts and 3 of 10 ACF, as well as stromal cells, showed mild-to-moderate immunopositivity of COX-2 protein. In positive cases, the expression was detected in approximately 50–80% of the total premalignant cells in such early lesions. Adjacent normal crypts revealed no immunostaining of COX-2 except for slight expression in cytoplasm of epithelium located at the crypt base or adjacent to lymph follicles. Immunostaining in β-catenin-accumulated crypts tended to be more evident than in ACF (Fig. 2).

**Frequency and crypt multiplicity of β-catenin-accumulated crypts and ACF**

The incidence of β-catenin-accumulated crypts and ACF is shown in Table I. In group 1, 4.77±1.55 β-catenin-accumulated crypts/cm² colonic mucosa and 9.33±4.82 ACF/cm² colonic mucosa were present. The dietary administration of celecoxib caused a significant reduction in the incidence of β-catenin-accumulated crypts: 2.51±1.88 in group 2 (47.4% inhibition), 1.45±1.25 in group 3 (69.6% inhibition) (Table I). Celecoxib was also found to reduce the incidence of ACF: 7.37±3.36 in group 2 (21.0% inhibition), 6.20±3.98 in group 3 (33.5% inhibition) (Table I). A significant decrease in the number of crypts/lesion in group 3 was observed in both β-catenin-accumulated crypts and ACF (P<0.001 and P<0.004 by Welch’s t test) when compared with those in group 1. The degree of decrease in crypt multiplicity in β-catenin-accumulated crypts (36.1%) was larger than that in ACF (12.5%) (Table II). Diameters of β-catenin-accumulated crypts in group 3 were also smaller than those in group 1 (data not shown). We did not observe β-catenin-accumulated crypts or ACF in group 4.

**Regional incidence of β-catenin-accumulated crypts**

In the present study, to determine regional effects of celecoxib, we examined three different segments of the colon; distal, medium-distal, and proximal-medium. In all segments, celecoxib significantly suppressed the occurrence of β-catenin-accumulated crypts (P<0.02 by Student’s t test). However, the decrease in the frequency of β-catenin-accumulated crypts in the proximal-medium segment (75.4% inhibition by 500 ppm celecoxib, and 80.2% inhibition...
bition by 1500 ppm celecoxib) exceeded that seen in the medium-distal (40.6% and 62.9%, respectively) or the distal segment (27.0% and 66.6%, respectively) (Table III).

AgNORs count/nucleus in β-catenin-accumulated crypts

Previously, we reported an increase of AgNORs count/nucleus of the epithelium in β-catenin-accumulated crypts, which may indicate cellular proliferation. In this study, we investigated the effects of celecoxib on the incidence and multiplicity of β-catenin-accumulated crypts and aberrant crypt foci (ACF).

Table I. Incidence of β-Catenin-accumulated Crypts and Aberrant Crypt Foci

| Group no. | Treatment          | No. of segments examined | No. of CAC (lesion) /cm² colonic mucosa | No. of ACF (lesion) /cm² colonic mucosa |
|-----------|--------------------|--------------------------|----------------------------------------|----------------------------------------|
| 1         | AOM alone          | 21                       | 4.77±1.55a                             | 9.33±4.82                              |
| 2         | AOM+500 ppm celecoxib | 21                      | 2.51±1.88b (47.4)                      | 7.37±3.36 (21.0)                       |
| 3         | AOM+1500 ppm celecoxib | 21                      | 1.45±1.25b (69.6)                      | 6.20±3.98b (33.5)                      |
| 4         | No treatment       | 21                       | 0                                      | 0                                      |

CAC, β-catenin-accumulated crypts; ACF, aberrant crypt foci.

Table II. Crypt Multiplicity of β-Catenin-accumulated Crypts and Aberrant Crypt Foci

| Group no. | Treatment          | No. of CAC (lesion) examined | No. of crypts/CAC | No. of ACF (lesion) examined | No. of crypts/ACF |
|-----------|--------------------|-----------------------------|-------------------|-------------------------------|------------------|
| 1         | AOM alone          | 66                          | 4.57±3.00a        | 98                            | 2.96±0.77        |
| 2         | AOM+500 ppm celecoxib | 31                      | 3.87±2.20 (15.3)  | 86                            | 3.08±0.92        |
| 3         | AOM+1500 ppm celecoxib | 26                      | 2.92±1.49b (36.1) | 78                            | 2.59±0.87b (12.5) |

CAC, β-catenin-accumulated crypts; ACF, aberrant crypt foci.

Table III. Regional Incidence of β-Catenin-accumulated Crypts and Aberrant Crypt Foci

A. β-Catenin-accumulated crypts

| Group no. | Treatment          | No. of segments examined | No. of CAC (lesion)/cm² in each segment |
|-----------|--------------------|--------------------------|----------------------------------------|
|           |                    |                          | Distal | Medium-distal | Proximal-medium |
| 1         | AOM alone          | 7                        | 4.67±1.80a | 5.07±1.32   | 4.58±1.75 |
| 2         | AOM+500 ppm celecoxib | 7                        | 3.41±2.10 (27.0) | 3.01±1.44b (40.6) | 1.13±1.37d (75.4) |
| 3         | AOM+1500 ppm celecoxib | 7                        | 1.56±1.30b (66.6) | 1.88±1.46b (62.9) | 0.90±1.11n (80.2) |
| 4         | No treatment       | 7                        | 0         | 0              | 0             |

CAC, β-catenin-accumulated crypts; ACF, aberrant crypt foci.

Table II. Aberrant crypt foci

| Group no. | Treatment          | No. of segments examined | No. of ACF (lesion)/cm² in each segment |
|-----------|--------------------|--------------------------|----------------------------------------|
|           |                    |                          | Distal | Medium-distal | Proximal-medium |
| 1         | AOM alone          | 7                        | 9.83±2.75 | 10.70±3.56 | 9.44±4.66 |
| 2         | AOM+500 ppm celecoxib | 7                        | 9.37±4.18 (4.7) | 6.21±1.77b (42.0) | 6.55±0.54 (30.6) |
| 3         | AOM+1500 ppm celecoxib | 7                        | 8.79±7.70 (10.6) | 5.18±1.64b (51.6) | 2.59±0.87e, f (72.6) |
| 4         | No treatment       | 7                        | 0         | 0              | 0             |

CAC, β-catenin-accumulated crypts; ACF, aberrant crypt foci.

Values in parentheses represent percentage inhibition compared to group 1.
Table IV. Mean Number of AgNORs/nucleus

| Group no. | Treatment | No. of CAC (lesion) examined | Mean no. of counts in CAC | No. of ACF (lesion) examined | Mean no. of counts in ACF | No. of normal crypts examined | Mean no. of counts in normal crypts |
|-----------|-----------|-----------------------------|--------------------------|----------------------------|---------------------------|----------------------------|----------------------------------|
| 1         | AOM alone | 15                          | 3.59±0.62<sup>a</sup>    | 15                         | 2.19±0.37                 | 30                         | 1.53±0.32                       |
| 2         | AOM+500 ppm celecoxib | 15                          | 2.43±0.39<sup>b</sup> (32.3) | 15                         | 2.11±0.36 (3.7)           | 30                         | 1.54±0.34                       |
| 3         | AOM+1500 ppm celecoxib | 15                          | 2.22±0.18<sup>c</sup> (38.2) | 15                         | 1.79±0.37<sup>c</sup> (12.5) | 30                         | 1.34±0.37                       |

CAC, β-catenin-accumulated crypts; ACF, aberrant crypt foci.

<sup>a</sup> Mean±SD.
<sup>b</sup> Significantly different from group 1 by Student’s t test (P<0.001).
<sup>c</sup> Significantly different from groups 1 and 2 by Student’s t test (P<0.03).

Values in parentheses represent percentage decrease compared to group 1.

crypts, suggesting that β-catenin-accumulated crypts have a higher activity of cell proliferation. The data for counts/nucleus in β-catenin-accumulated crypts, ACF and adjacent normal crypts are shown in Table IV. The mean AgNORs count/nucleus of β-catenin-accumulated crypts in both groups 2 and 3 was significantly smaller than that in the control group (group 1) (P<0.001 by Student’s t test). The degree of reduction of AgNORs count/nucleus in β-catenin-accumulated crypts exceeded that seen in ACF.

DISCUSSION

Our previous studies characterizing β-catenin-accumulated crypts at the molecular and cellular levels have implicated early appearing crypts as intermediate lesions leading to colon cancer. β-Catenin-accumulated crypts possess characteristic morphology, and increased proliferation kinetics, and frequent mutations of β-catenin gene, a key gene in the process of colon cancer development in rats. Since inhibition of the occurrence and advancement of premalignant lesions has potential for cancer prevention, it is important to examine whether chemopreventive agents suppress the occurrence of these premalignant lesions in rats. In this report, we evaluated possible modifying effects of a selective COX-2 inhibitor, celecoxib, on the frequency and growth of β-catenin-accumulated crypts. Selection of this agent in the present study was based on previous observations by Kawamori and Reddy et al. that the inhibitory effects of celecoxib exceeded those of other NSAIDs and the agent lacks serious side effects. It is noteworthy that celecoxib inhibited occurrence and advancement of β-catenin-accumulated crypts. These findings represent additional evidence that β-catenin-accumulated crypts are premalignant lesions of colon cancer. The results also suggest that celecoxib prevents the initial stage of colon carcinogenesis, and that the COX-2 inhibitor is a good candidate agent for prevention of colorectal carcinogenesis.

ACF are detectable in cancer-predisposed colonic mucosa with methylene blue-staining and are considered to be an appropriate target for chemopreventive drug development. Therefore, ACF have been used as a biomarker in studies of cancer prevention. Previous studies, including molecular analysis, have focused on the significance of ACF as early events in the colon carcinogenesis. However, recent studies also reported that incidence of ACF is not always reflected in the occurrence of colon cancers. In the present study, celecoxib also reduced the incidence of ACF in the same manner as described previously. However, the efficacy of celecoxib in reducing the frequency and growth of β-catenin-accumulated crypts was greater than that against ACF. Accordingly, the results seem to indicate that β-catenin-accumulated crypts are a novel biomarker that will be useful in studies aimed at discovering chemopreventive agents against development of colorectal cancers.

It has been shown that COX-2 inhibitor acts by its interaction with the active site of the enzyme. In the present study, excess COX-2 protein was detected in cytoplasm of β-catenin-accumulated crypts. Although the exact mechanisms by which celecoxib suppresses β-catenin-accumulated crypts remains to be elucidated, accumulating evidence suggests that overexpression of COX-2 may induce growth stimulation in colon cancer cells. We have demonstrated that celecoxib significantly decreases proliferative activity in β-catenin-accumulated crypts. Our results may suggest that celecoxib inhibits the proliferative activity of cellular population in premalignant lesions through inhibition of the increased COX-2 activity in such early appearing lesions.

It is also interesting to note that the efficacy of celecoxib in inhibiting premalignant lesions was different in the proximal and distal colon. In this study, the suppressive efficacy in the proximal segment was greater than that in the distal colon. These findings are in agreement with the previous study showing that a COX inhibitor, piroxicam, markedly reduced the occurrence of colon tumors in the proximal colon.
cancerogenesis are related to the modulation of cell proliferation activity in putative premalignant lesions. Moreover, β-catenin-accumulated crypts may be a novel target for prevention of colorectal cancerogenesis, and could also be useful to evaluate chemopreventive agents.

ACKNOWLEDGMENTS

We thank Dr. Karen Seibert (Searle Research and Development) for providing celecoxib. We also thank K. Takahashi, C.

REFERENCES

1) Thun, M., Namboodiri, M. and Heath, C. Aspirin use and reduced risk of fatal colon cancer. *N. Engl. J. Med.*, **325**, 1593–1596 (1991).
2) Giardiello, F., Hamilton, S., Krush, A., Plantadoti, S., Hytind, L., Celano, P., Booker, S., Robinson, C. and Offerhaus, G. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N. Engl. J. Med.*, **328**, 1313–1316 (1993).
3) Rao, C., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V. and Reddy, B. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. *Cancer Res.*, **55**, 1464–1472 (1995).
4) Reddy, B., Tokumo, K., Kulkarni, N., Aligia, C. and Kelloff, G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. *Carcinogenesis*, **13**, 1019–1023 (1992).
5) Kawamori, T., Rao, C., Seibert, K. and Reddy, B. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. *Cancer Res.*, **58**, 409–412 (1998).
6) Yoshimi, N., Shimizu, M., Matsunaga, K., Yamada, Y., Fuji, K., Harax, A. and Mori, H. Chemopreventive effect of N-(2-cylohexylxoyl-4-nitrophenyl)methylene sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. *Jpn. J. Cancer Res.*, **90**, 406–412 (1999).
7) Reddy, B., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K. and Rao, C. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. *Cancer Res.*, **60**, 293–297 (2000).
8) Vogelstein, B., Fearon, E., Hamilton, S., Kern, S., Preisinger, A., Leppert, M., Nakamura, Y., White, R., Smits, A. and Bos, J. Genetic alterations during colorectal tumor development. *N. Engl. J. Med.*, **319**, 525–532 (1988).
9) Powell, S., Zilz, N., Beazer-Barclay, Y., Bryan, T., Hamilton, S., Shibudeau, S., Vogelstein, B. and Kinzler, K. APC mutations occur early during colorectal tumorigenesis. *Nature*, **359**, 235–237 (1992).
10) Polakos, P. The adenomatous polyposis coli (APC) tumor suppressor. *Biochim. Biophys. Acta*, **1332**, F127–F147 (1997).
11) Takahashi, M., Fukuda, K., Sugimura, T. and Wakabayashi, K. Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. *Cancer Res.*, **58**, 42–46 (1998).
12) Aberle, H., Bauer, A., Stappert, J., Kispert, A. and Kemler, R. Beta-catenin is a target for the ubiquitin-proteasome pathway. *EMBO J.*, **16**, 3797–3804 (1997).
13) Morin, P., Sparks, A., Korinek, V., Barker, N., Clevenger, H., Vogelstein, B. and Kinzler, K. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science*, **275**, 1787–1790 (1997).
14) Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roosen, J., Destree, O. and Clevenger, H. XTc-3 transcription factor mediates beta-catenin-induced axis formation in *Xenopus* embryos. *Cell*, **86**, 391–399 (1996).
15) Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R. and Birchmeier, W. Functional interaction of beta-catenin with the transcription factor LEF-1. *Nature*, **382**, 638–642 (1996).
16) He, T., Sparks, A., Rago, C., Heremeking, H., Zawel, L., da Costa, L. T., Morin, P., Vogelstein, B. and Kinzler, K. Identification of c-MYC as a target of the APC pathway. *Science*, **281**, 1509–1512 (1998).
17) Tetsu, O. and McCormick, F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*, **398**, 422–426 (1999).
18) Yamada, Y., Yoshimi, N., Hirose, Y., Kawabata, K., Matsunaga, K., Shimizu, M., Harax, A. and Mori, H. Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. *Cancer Res.*, **60**, 3323–3327 (2000).
19) Yamada, Y., Yoshimi, N., Hirose, Y. and Mori, H. Sequential analysis of morphological and biological properties of β-catenin-accumulated crypts, provable preneoplastic lesions independent of aberrant crypt foci in rat colon carcinogenesis. *Cancer Res.*, **61**, 1874–1878 (2001).
20) Bird, R. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. *Cancer Lett.*, **37**, 147–151 (1987).
Chemoprevention of β-Catenin-accumulated Crypts

21) Reddy, B., Rao, C. and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. *Cancer Res.*, 56, 4566–4569 (1996).

22) Tanaka, T., Takeuchi, T., Nishikawa, A., Takami, T. and Mori, H. Nucleolar organizer regions in hepatocarcinogenesis induced by N-2-fluorenylacetamide in rats: comparison with bromodeoxyuridine immunohistochemistry. *Jpn. J. Cancer Res.*, 80, 1047–1051 (1989).

23) Dashwood, R., Suzuki, M., Nakagama, H., Sugimura, T. and Nagao, M. High frequency of beta-catenin (ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. *Cancer Res.*, 58, 1127–1129 (1998).

24) Kawamori, T., Tanaka, T., Hará, A., Yamahara, J. and Mori, H. Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. *Cancer Res.*, 55, 1277–1282 (1995).

25) Bird, R. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. *Cancer Lett.*, 93, 55–71 (1995).

26) Zheng, Y., Kramer, P., Lubet, R., Steele, V., Kelloff, G. and Pereira, M. Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. *Carcinogenesis*, 20, 255–260 (1999).

27) Rao, C., Wang, C., Simi, B., Lubet, R., Kelloff, G., Steele, V. and Reddy, B. Enhancement of experimental colon cancer by genistein. *Cancer Res.*, 57, 3717–3722 (1997).

28) Gierse, J., Koboldt, C., Walker, M., Seibert, K. and Isakson, P. Kinetic basis for selective inhibition of cyclo-oxygenases. *Biochem. J.*, 339, 607–614 (1999).

29) Kinoshita, T., Takahashi, Y., Sakashita, T., Inoue, H., Tanabe, T. and Yoshimoto, T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. *Biochim. Biophys. Acta*, 1438, 120–130 (1999).

30) Sheng, H., Shao, J., Kirkland, S., Isakson, P., Coffey, R., Morrow, J., Beauchamp, R. and DuBois, R. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. *J. Clin. Invest.*, 99, 2254–2259 (1997).

31) Liu, T., Mokuolu, A., Rao, C., Reddy, B. and Holt, P. Regional chemoprevention of carcinogen-induced tumors in rat colon. *Gastroenterology*, 109, 1167–1172 (1995).